How to value a pre-revenue startup when there are no comps

I price companies for a living. So let me start with the part most founders get backwards. A pre-revenue valuation is not the answer to "what is this company worth." There is no intrinsic value to find. A pre-revenue valuation is a negotiated price, set by ownership math, by the story you can defend, and by what a lead investor will actually pay this quarter. I have priced more than a thousand private companies and worked on deals up to roughly $26 billion, and the discipline is the same at both ends: you are not calculating worth, you are pricing consequences. At seed, the consequence you are pricing is the down round you might trigger eighteen months from now.

Hold that idea. Everything below serves it.

Why pre-revenue breaks the usual tools

Every valuation method you learned assumes something to multiply. A revenue multiple needs revenue. An EBITDA multiple needs earnings. A discounted cash flow needs cash flows. Pre-revenue, you have none of those. You have a deck, a team, maybe a prototype, and a market you are claiming is large. The clean comps do not exist either. Two pre-seed AI companies can look identical on paper and price 5x apart because one founder sold a company before and the other did not. The usual machinery has nothing to bite on.

So the professional move is not to fake the inputs. It is to switch from computing a number to triangulating a range. You are looking for a defensible band, then negotiating within it. Anyone who hands you a single precise pre-revenue valuation, to the dollar, is selling you confidence they do not have.

What a pre-revenue valuation actually is

Strip away the methods and a seed valuation is three things stacked together. First, ownership math: the lead wants to own a target percentage, usually around 10 to 20 percent, and the round size plus that target back-solves to a post-money. Second, narrative: how big the outcome could be and how credibly you can tell that story. Third, the clearing price: what a real lead will actually wire, given the other deals on their desk this month. The methods below are tools for triangulating that band. They do not override it.

This is also why so many early rounds use a SAFE or a convertible note with a valuation cap. The cap is not the valuation. It is a deferral. You are agreeing to settle the price later, at the priced round, while setting a ceiling now. Founders treat the cap like a trophy. It is a liability you will mark against at the next round, and if you set it too high, the next investor either pays up to your fantasy or prices you below it and resets everyone.

The methods that help you triangulate

None of these finds the number. Each one fences the range from a different side. Use three or four, not one.

The Berkus Method, built by angel Dave Berkus in the mid-1990s, assigns dollar value to risk you have retired, not to intrinsic worth. Five elements, sound idea, prototype, quality team, strategic relationships, and product rollout, each worth up to $500,000, capping pre-money at $2.5 million. The strength is that it forces an honest, risk-by-risk conversation instead of a fake spreadsheet. The weakness is the ceiling. Berkus never indexed those figures for inflation, so a $2.5 million cap looks absurd next to Carta's median seed pre-money of $16 million in Q3 2025, with PitchBook-NVCA putting it at $15.8 million the same quarter. Use Berkus to structure the risk discussion, not to set the price.

The Scorecard Method, developed by Bill Payne, fixes the staleness by starting from the median pre-money of recent comparable rounds in your region and sector, then adjusting on weighted factors: team up to 30 percent, market size up to 25 percent, product and technology only up to 15 percent, then competition, channels, and capital needs. Team and market dominate; product ranks below both. Payne's logic: a great team fixes a flawed product, but a great product does not fix a bad team. You score each factor against the norm, where 100 percent is average and 125 percent is a quarter better than the comparable, then multiply, sum to a single multiplier, and apply it to the regional median. The method is only as good as your comp data, which most founders cannot see. It is your best tool where decent benchmarks exist.

Risk Factor Summation, from the Ohio TechAngels, widens the lens to twelve risks, including the ones the other methods ignore: legislation, litigation, international, reputation. You start from a regional base and score each risk from +2 to -2, with every step worth $250,000. Its value is breadth. Its flaw is the same fixed increment and the same subjectivity. It is a checklist, not an oracle.

The Venture Capital Method, introduced by Harvard's Bill Sahlman in 1987, mirrors how investors actually think, because it works backward from the exit. Estimate a terminal value, divide by the return the investor needs, and you get today's post-money; subtract the new money for pre-money. Seed investors target 20x to 30x because most of the portfolio dies and the winners carry the fund. Payne notes later dilution can cut realized returns by 3x to 5x, which is part of why the multiple is so steep. This is the cross-check that tells you whether a number lets an investor hit their fund math. If your ask only pencils at a 40x exit nobody believes, the number is wrong.

Then there is the method that quietly governs all of it: comparable recent financings. The median pre-money of companies like yours, same stage, sector, and geography, raised in the last few quarters. This is the gravitational center. Everything else is you arguing why you sit above or below it.

Why DCF mostly fails here

Founders reach for discounted cash flow because it feels rigorous. Pre-revenue, it is theater. A DCF compounds a five-year projection you invented, then discounts it back. Change the growth rate two points or the discount rate three, and the answer triples. You are not modeling a business, you are laundering an assumption through arithmetic until it looks objective. Investors know this. A polished pre-revenue DCF does not raise your number; it tells a sophisticated lead you do not understand which tools apply at which stage. Save it for when you have revenue to discount.

How investors actually set the number

Here is the part the methods dance around. A seed lead does not build up to your valuation from a model. They start from the ownership they need and the check they are writing. They want, say, 15 percent. They are putting in $3 million. That implies a $20 million post-money, $17 million pre. Then they reach for Scorecard and comps to check whether $17 million is sane for your stage and sector, and for the VC Method to confirm it still clears their return math after dilution. The qualitative methods are not the engine. They are the sanity rails around a number that ownership targets and current market norms have already mostly set. Right now that means roughly $15 to $16 million median seed pre-money, with real spread by sector and by founder pedigree. Your job is to know where in that distribution you honestly sit.

The mistakes that cost you later

I have watched the same errors cost founders real money, almost always at the next round, not this one.

Anchoring too high is the expensive one. A pre-money that beats the market feels like winning. It sets a bar your next eighteen months of progress has to clear, and if you miss, you raise a down round. A down round resets option pools, triggers anti-dilution, dents morale, and signals weakness to every future investor. The number that flatters you today is the one that traps you next year.

Ignoring dilution is the quiet one. Founders fixate on this round's percentage and forget that seed, Series A, and Series B each take another slice. Optimize for a clean ownership path across all of them, not a hero valuation in round one.

Fake projections are the tell. A pre-revenue hockey stick to $50 million in year three does not impress a professional. It marks you as someone who does not know what is knowable. Show the assumptions you can defend and the milestones that retire risk. Defensible beats impressive every time.

How I triangulate and defend a number

When I price one of these, I run the comps first to find the regional, sector median, which is my center of gravity. I run Scorecard to argue, with evidence, where above or below that median this company honestly sits. I run the VC Method as a ceiling, to confirm a real investor can pay it and still hit their fund math after dilution. Berkus and Risk Factor Summation I use as conversation structure, to make sure no major risk goes unpriced. Five inputs, one range. Then I pick a number inside that range I can defend line by line, and I leave deliberate room beneath my ceiling, because the goal is not the highest number I can extract. It is the highest number I can grow into without triggering a reset.

That is the whole discipline. A pre-revenue valuation is a negotiated price, not a discovered truth, and the founders who win are not the ones who anchor highest. They are the ones who price the consequences, defend a range, and raise at a number their next eighteen months can actually justify.

Common questions

How do you value a pre-revenue startup with no comparable companies?

You triangulate a range instead of computing one number. Start from the median pre-money of recent rounds in your stage, sector, and region as your center of gravity. Use the Scorecard Method to argue where above or below that median you honestly sit, and the VC Method as a ceiling to confirm an investor can pay it and still hit their return math. There is no intrinsic value to find. You are pricing a negotiation, then defending a band.

Is the Berkus Method still useful when seed valuations are far above its $2.5 million cap?

Yes, but not as a price. Berkus assigns dollar value to risk you have retired across five elements, which forces an honest, risk-by-risk conversation no spreadsheet gives you. The flaw is that Dave Berkus never indexed the figures for inflation, so the $2.5 million ceiling looks absurd next to Carta's $16 million median seed pre-money in late 2025. Use Berkus to structure the risk discussion. Use comps and the VC Method to set the number.

Why does discounted cash flow fail for pre-revenue startups?

Because you are discounting a five-year projection you invented. Move the growth rate two points or the discount rate three, and the answer triples. A polished pre-revenue DCF does not raise your valuation. It signals to a sophisticated lead that you do not understand which tools apply at which stage. There are no cash flows yet to discount, so the rigor is cosmetic. Save DCF for when you have revenue.

What is the most expensive mistake founders make on valuation?

Anchoring too high. A pre-money that beats the market feels like winning, but it sets a bar your next eighteen months of progress has to clear. Miss it and you raise a down round, which resets option pools, triggers anti-dilution, dents morale, and signals weakness to every future investor. The number that flatters you today is the one that traps you next year. Raise at a number you can grow into.

Should I set a high valuation cap on my SAFE?

Be careful. The cap is not your valuation. It is a deferral that sets a ceiling now and settles the real price at the priced round. Set it too high and your next investor either pays up to a number you cannot justify or prices you below the cap and resets everyone. Founders treat the cap like a trophy. It is a liability you will mark against later. Set it at a level your next eighteen months can defend.

Related reading

• How to value an AI-native startup when the model is rented.
• A field guide to pricing private companies, stage by stage.
• The valuation index: every method, when each one applies.
• Try the valuation calculator and triangulate your own range.

Go deeper

If you are raising a pre-seed or seed round, or staring at a SAFE cap you are not sure you can defend, let's work the actual numbers together, or read more of how I think about it.

Tomasz Felpel is an investor, founder, and advisor in private markets and healthcare, based in New York. He is a three-time founder of Value Alpha, an AI-powered private-markets valuation platform, Sonnerie VC, an early-stage healthcare venture firm, and Pond. Previously he led corporate development and M&A at Fortune 500 scale, pricing more than 1,000 private companies. Columbia Business School EMBA. Read the full story.